Followers | 826 |
Posts | 32350 |
Boards Moderated | 8 |
Alias Born | 03/22/2016 |
Monday, January 23, 2023 10:42:24 AM
Recent MREO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 12:47:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 12:46:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:50:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:47:50 PM
- Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/12/2024 09:35:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:05:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:05:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:19:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:09:32 PM
- Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/13/2024 12:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:15:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:30:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 08:15:42 PM
- Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market • GlobeNewswire Inc. • 06/14/2024 11:50:48 AM
- Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) • GlobeNewswire Inc. • 06/11/2024 09:47:59 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:18:09 PM
- Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 11:30:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 01:54:37 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/23/2024 10:38:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:16:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/15/2024 08:49:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:19:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:06:47 PM
- Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2024 08:01:44 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • Oct 3, 2024 7:00 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM